Immune checkpoint blockade using anti‐PD‐1/PD‐L1 or anti‐CTLA‐4 monoclonal
antibodies (mAbs) has revolutionized cancer treatment. However, many types of cancer do …

The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the
enzymes that generate and degrade them, and the receptors that receive their signals are all …

Blocking the PD-1/PD-L1 interaction has become an important strategy for tumor therapy,
which has shown outstanding therapeutic effects in clinical settings. However, unsatisfactory …

Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the
tumor microenvironment. Strategies for targeting LPA signaling have recently entered …

Checkpoint inhibitors are relatively inefficacious in head and neck cancers, despite an
abundance of genetic alterations and a T-cell–inflamed phenotype. One significant barrier to …

Dear Editor, PD-L1 is a well-known transmembrane protein, which is highly expressed on
many types of cancer cells. By binding to its receptor PD-1 on T cells, PD-L1 significantly …

Simple Summary In a tumor context, antitumor immune cells mediate an inflammatory
response after activating a metabolic switch to kill cancer cells. However, tumors develop …

Targeting immune checkpoint PD-1 or its ligand PD-L1 blockade has achieved a great
therapeutic effect in a variety of cancer types. However, the overall response rate and …

Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane
phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled …

Lysophosphatidic acid (LPA) is a bioactive lipid that interacts with G protein-coupled
transmembrane LPA receptors (LPA1 to LPA6). LPA mediates a variety of cellular responses …